[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP9802971A1 - Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére - Google Patents

Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére

Info

Publication number
HUP9802971A1
HUP9802971A1 HU9802971A HUP9802971A HUP9802971A1 HU P9802971 A1 HUP9802971 A1 HU P9802971A1 HU 9802971 A HU9802971 A HU 9802971A HU P9802971 A HUP9802971 A HU P9802971A HU P9802971 A1 HUP9802971 A1 HU P9802971A1
Authority
HU
Hungary
Prior art keywords
treatments
mmp inhibitors
ocular angiogenesis
matrix metalloproteinase
inhibitors
Prior art date
Application number
HU9802971A
Other languages
English (en)
Inventor
Niall Stephen Doherty
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU9802971D0 publication Critical patent/HU9802971D0/hu
Publication of HUP9802971A1 publication Critical patent/HUP9802971A1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Ajelen találmány a mátrix metallőprőteináz inhibitőrők közül előnyösenazők alkalmazására vőnatkőzik, amelyek mátrix metallőprőteináz-2-vagy-9-specifikűs hatással rendelkeznek a szemérképződés kezelésében vagymegelőzésében. A találmány tárgyát képezik a hatóanyagőt tartalmazógyógyszerkészítmények is. ŕ
HU9802971A 1997-12-19 1998-12-18 Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére HUP9802971A1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6826197P 1997-12-19 1997-12-19

Publications (2)

Publication Number Publication Date
HU9802971D0 HU9802971D0 (en) 1999-02-01
HUP9802971A1 true HUP9802971A1 (hu) 2000-08-28

Family

ID=22081436

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802971A HUP9802971A1 (hu) 1997-12-19 1998-12-18 Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére

Country Status (9)

Country Link
EP (1) EP0930067A3 (hu)
JP (2) JPH11263735A (hu)
KR (1) KR19990063202A (hu)
AU (1) AU761585B2 (hu)
CA (1) CA2256303A1 (hu)
HU (1) HUP9802971A1 (hu)
IL (1) IL127496A0 (hu)
NZ (1) NZ333457A (hu)
ZA (1) ZA9811629B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT977733E (pt) * 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
BR9814643A (pt) 1997-11-14 2000-10-03 Searle & Co Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) * 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EE200100410A (et) 1999-02-08 2002-12-16 G.D. Searle & Co. Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001070696A1 (fr) * 2000-03-21 2001-09-27 Ishihara Sangyo Kaisha, Ltd. Derives de nitroethenamine ou sels desdits composes, et compositions pharmaceutiques contenant ces derives ou ces sels
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
CA2444704C (en) 2001-04-23 2012-07-10 University Of Virginia Patent Foundation Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
WO2002092588A2 (en) 2001-05-11 2002-11-21 Pharmacia Corporation Aromatic sulfone hydroxamates and their use as protease inhibitors
DK1423115T3 (da) * 2001-08-06 2009-06-15 Childrens Medical Center Nitrogen-substituerede thalidomidanalogers antiangiogenetiske aktivitet
US7119203B2 (en) 2002-04-25 2006-10-10 Pharmacia Corporation Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004080452A1 (ja) * 2003-03-10 2004-09-23 Shionogi & Co., Ltd. 網膜疾患治療薬
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
US20090018094A1 (en) * 2006-12-01 2009-01-15 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
CA2285372A1 (en) * 1997-04-01 1998-10-08 Melwyn A. Abreo Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9707333D0 (en) * 1997-04-11 1997-05-28 British Biotech Pharm Metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU761585B2 (en) 2003-06-05
CA2256303A1 (en) 1999-06-19
HU9802971D0 (en) 1999-02-01
JPH11263735A (ja) 1999-09-28
JP2001122775A (ja) 2001-05-08
EP0930067A2 (en) 1999-07-21
ZA9811629B (en) 2000-06-19
IL127496A0 (en) 1999-10-28
KR19990063202A (ko) 1999-07-26
NZ333457A (en) 2001-06-29
AU9722498A (en) 1999-07-08
EP0930067A3 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
ATE182581T1 (de) Metalloproteinase-inhibitoren
ATE182137T1 (de) Peptidylderivate als inhibitoren von metalloproteinase
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
NO20022525L (no) Farmasöytiske formuleringer inneholdende zolmitriptan
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
DE50109650D1 (de) Topische behandlung bei der mastalgie
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
DE69910787D1 (de) Neuartige, pharmazeutisch aktive verbindung
PT862433E (pt) Composicao farmaceutica espumante topica para o tratamento de dermatoses induzidas por pityrosporum oval